About the Project |  FAQs |  Glossary |  Data Sources |  Bibliography |  Complete Indicator List

Indicator Details: SGLT2 Inhibitor Use (%) Among Patients with CKD and Diabetesa
Data Sources
Stratification and Year Choices:

  • Clinformatics Commercial

  View Data By:
  Chart Format

  Chart Colors

Select a state from the dropdown below


Filter By:

Sort By:

a Adults aged 20–64 years with kidney damage (i.e., having protein in the urine) (CKD stages 1–2) or with an estimated glomerular filtration rate (eGFR)—a measure of kidney function— <60 mL/min/1.73 m2 (CKD stages 3–5). The higher the stage, the more advanced the disease. Stage 5 is kidney failure. Estimates were not adjusted for age.

In 2018, 10% of patients with CKD and diabetes were receiving SGLT2 inhibitors, for patients aged 20-64 years old enrolled in Commercial insurance from OPTUM Clinformatics.
Chart Explanation: Chart Explanation: Use of SGLT2 inhibitors was higher (14%) among adults with diabetes and early CKD (stage 1 or 2) compared to those with more advanced CKD (stages 3–5).

The Clinformatics™ Commercial dataset provides paid medical and prescription claims and enrollment information for participants in commercial insurance plans. CKD and Diabetes are defined using International Classification of Diseases (ICD)-9-Clinical Modification (CM) or ICD-10-CM diagnosis codes. Outpatient pharmacy records of prescriptions filled for patients were examined for drugs in the sodium-glucose cotransporter-2 (SGLT2) inhibitors class.

Description of Measure

The percentage of patients diagnosed with CKD and DM (by ICD-9-CM or ICD-10-CM codes) that received SGLT2 inhibitors.

Data Source

Clinformatics Commercial from Optum Clinformatics™ Data Mart Database (OptumInsight, Eden Prairie, MN)

Type of Data Source


Data Set

Clinformatics Commercial enrollees age 20-64 years..

Health Care System Data


Regional or National

Nation-wide but only places with the specific insurance coverage

Demographic Group

Privately insured working age people.


Patients in denominator with prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors


Patients age 20-64 years old enrolled in Clinformatics Commercial insurance and diagnosed with CKD and DM.

Primary Indicator Method of Measurement

Medical and pharmacy claims

Period Currently Available


ICD-9-CM Codes for CKD

016.0; 095.4; 189.0,189.9; 223.0; 236.91; 250.4; 271.4; 274.1; 283.11; 403; 404; 440.1; 442.1; 477.3; 572.4; 581-588; 591; 642.1; 646.2; 753.12-753.19; 753.2; 794.4

ICD-10-CM Codes for CKD

A18.11, A52.75, B52.0, C64.x, C68.9, D30.0x, D41.0x-D41.2x, D59.3, E08.2x, E09.2x, E10.2x, E10.65, E11.2x, E11.65, E13.2x, E74.8, I12.xx, I13.0, I13.1x, I13.2, K76.7, M10.3x, M32.14, M32.15, N01.x-N08.x, N13.1, N13.1x-N13.39, N14.x,N15.0, N15.8, N15.9, N16, N17.x, N18.1-N18.5, N18.8, N18.9, N19, N25.xx, N26.1, N26.9, O10.4xx, O12.xx, O26.83x, O90.89, Q61.02, Q61.1x-Q61.8, Q26.0-Q26.39, R94.4

Suggested Citation:
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States.
website. http://www.cdc.gov/ckd